A prospective cohort study was performed to determine the optimal dose of vancomycin to maintain a serum trough concentration of at least 15 to 20 mg/l and to assess the efficacy of this target vancomycin concentration in the treatment of methicillin-resistant Staphylococcus aureus pneumonia. Vancomycin pharmacokinetic parameters were estimated using a CAPSIL software program from serum concentrations of 141 patients with pneumonia treated with vancomycin, regardless of methicillin-resistant Staphylococcus aureus status, at a 28-bed medical intensive care unit. Vancomycin trough concentrations and other pharmacokinetic parameters were compared between five groups of patients differing in their renal function: 1) creatinine clearance ≥60 ml/minute, 2) creatinine clearance 30 to 60 ml/minute, 3) creatinine clearance <30 ml/minute, 4) on intermittent haemodialysis, and 5) on continuous renal replacement therapy. More than 70% of patients failed to reach the recommended therapeutic serum trough concentrations: a higher dose of vancomycin is necessary to maintain serum trough concentration at 15 to 20 mg/l, particularly in critically ill patients with creatinine clearance above 60 ml/minute and in those on intermittent haemodialysis. Among patients with methicillin-resistant Staphylococcus aureus pneumonia, no significant differences were observed in the treatment success rate, length of intensive care unit stay, and intensive care unit mortality rate between patients with vancomycin trough concentrations of >20 mg/l, 15 to 20 mg/l and <15 mg/l.
Methicillin-resistant
Staphylococcus aureus (MRSA) is an increasingly common cause of hospitalacquired infection among patients in intensive care [1] [2] [3] [4] . Vancomycin is the treatment of choice for life-threatening MRSA pneumonia. However, the hospital mortality rate for MRSA pneumonia exceeds 50%, despite the use of vancomycin [5] [6] [7] [8] .
Staphylococcal resistance to vancomycin may develop following prolonged exposure to low serum vancomycin concentrations, which leads to an increase in the minimal inhibitory concentration (MIC) 5 . Vancomycin exhibits restricted intrapulmonary distribution 9, 10 , and several authors have suggested that high serum trough concentrations of vancomycin (i.e. at least 15 to 20 mg/l) are needed to achieve optimal treatment outcomes in patients with MRSA pneumonia [11] [12] [13] [14] . According to the 2005 American Thoracic Society and Infectious Diseases Society of America guidelines for the treatment of healthcare-associated pneumonia, the serum trough concentration of vancomycin should be between 15 to 20 mg/l to maximise lung penetration in patients with MRSA pneumonia 15 . However, few clinical studies have been performed to validate the efficacy and safety of this approach [16] [17] [18] .
This study was conducted to determine the optimal dose of vancomycin to maintain serum trough concentration of at least 15 to 20 mg/l in critically ill patients with pneumonia and to assess the efficacy of this dose of vancomycin in the treatment of MRSA pneumonia.
MATERIALS AND METHODS Design and population
This prospective study was conducted in a 28bed medical intensive care unit in the 2800-bed Asan Medical Center in Seoul, Korea, from August 2005 to July 2007. The study was approved by the hospital's institutional review board; informed consent was not required because this was an observational study.
Patients were included if they were 18 years of age or older, were diagnosed with nosocomial pneumonia and had been treated with vancomycin for 72 hours or more, regardless of whether they had an MRSA infection.
Data collection
The medical and laboratory records of eligible patients were retrospectively reviewed in addition to prospectively collected pharmacokinetic data. Demographic, laboratory and clinical data were collected, including age, gender, body weight, white blood cell count, C-reactive protein, serum albumin, serum creatinine, Acute Physiology and Chronic Health Evaluation II scores at the time of intensive care unit (ICU) admission and initial vancomycin treatment, underlying diseases, microbiologic test results, vancomycin therapy data (date, dose and duration), creatinine clearance (CrCl) estimated by the Cockcroft-Gault formula at the time of vancomycin serum sampling, chest radiography findings, length of ICU stay, ventilation status and ICU discharge status.
Vancomycin treatment and serum sampling
All patients were treated with vancomycin, receiving 1.0 g q 12 hours initially. In patients with renal impairment, the dose of vancomycin was reduced according to published recommendations 19,20 : 1.0 g q 12 hours in patients with normal renal function; 1.0 g q 24 to 48 hours in patients with CrCl 30 to 60 ml/minute; 1.0 g q 72 to 96 hours in patients with CrCl <30 ml/minute; 1.0 g q 72 to 96 hours in patients on intermittent haemodialysis (IHD) and from 500 mg to 1.0 g q 24 hours in patients on continuous renal replacement therapy. Serum trough concentrations were obtained ≤30 minutes before administration of the next dose and serum peak concentrations were obtained at steady state one hour after vancomycin administration. Steady state was considered to be reached after three to five doses of vancomycin. Serum vancomycin concentration was measured using a fluorescence polarisation immunoassay (TDx, Abbott Diagnostics, Chicago, IL, USA).
Pharmacokinetic analysis
A commercial CAPSIL software program (SIMKIN Inc., Gainesville, FL, USA) was used for the pharmacokinetic analysis, assuming a onecompartment open model. Using this program, pharmacokinetic parameters such as half-life, volume of distribution, vancomycin clearance and area under the concentration curve over a 24-hour period were generated and the predicted concentration was calculated for each patient. Optimal vancomycin doses were then corrected by a pharmacist, with the aim of maintaining serum trough concentrations of at least 15 to 20 mg/l. The dose was administered intravenously by intermittent bolus over at least two hours in divided doses every six to 12 hours, based on the pharmacokinetic analysis for each patient.
Definitions and classifications
Acute Physiology and Chronic Health Evaluation II scores were calculated on the day of ICU admission and on the first day of vancomycin treatment.
Clinical diagnosis of pneumonia was made according to the criteria established by the American College of Chest Physicians 21 and was defined as the occurrence of a new and persistent radiographic infiltrate in conjunction with two of the following: 1) fever (≥38°C) or hypothermia (<36°C), 2) leukocytosis or leukopenia (WBC >10,000 /mm 3 or <4000 /mm 3 ) and 3) purulent tracheal aspirate or sputum. MRSA pneumonia was diagnosed by a positive MRSA culture from samples obtained from sputum, tracheal or bronchial aspirate, or by semiquantitative culture methods.
Patients were classified into five subgroups according to CrCl using the Cockroft-Gault method 22 : 1) CrCl ≥60 ml/minute, 2) CrCl 30 to 60 ml/minute, 3) CrCl <30 ml/minute, 4) on IHD, and 5) on continuous renal replacement therapy.
Two populations were defined for the data analysis. The first population comprised all the patients receiving vancomycin treatment for more than 72 hours. The other was an intention-to-treat population that comprised patients with MRSA pneumonia who received vancomycin treatment for a minimum of five days.
Treatment outcome was determined by a physician as either a success or failure after at least 14 days of vancomycin treatment. Treatment success was defined as the resolution of baseline signs and symptoms of MRSA pneumonia in conjunction with the improvement or lack of progression of all abnormalities on the chest radiograph 23 . Treatment failure was defined as the change of vancomycin to another drug, due to serious adverse events or a lack of efficacy, or death.
Statistical analysis
Values were expressed as percentages or means with standard deviations. SPSS package, version 12.0 (SPSS Inc., Chicago, IL, USA), was used for analysis. Patient baseline characteristics and categorical variables were compared by the χ 2 test or Fisher's exact test and continuous variables were compared by Student's t-test or analysis of variance.
All statistical tests were two-tailed. P values of <0.05 were considered statistically significant.
RESULTS
Between August 2005 and July 2007, 141 patients were enrolled in the study. The baseline characteristics of the patients are summarised in Table 1 . MRSA was identified in 53.2% of the patients and the ICU mortality rate was 48.9%. Notably, 22.7% of the patients had a vancomycin trough concentration of >20 mg/l and 55.3% of <15 mg/l. Only 22% had a trough concentration within the target range of 15 to 20 mg/l.
We categorised the patients into five groups according to their renal function and compared the pharmacokinetic data, including serum vancomycin concentration and dose regimens ( Table 2 ). The mean trough concentration was below 15 mg/l in patients with CrCl >60 ml/minute and was lowest in patients in the IHD group. The vancomycin clearance of the patients on IHD was similar to patients with CrCl of 10 to 30 ml/minute, although a smaller dosage was administered to the IHD group. The initial and corrected dosages were compared and were significantly higher in the CrCl >60 ml/min and IHD groups (Figure 1 ). This suggests that patients with normal renal function or those on IHD are more likely to require higher doses of vancomycin to maintain serum trough concentrations of at least 15 to 20 mg/l.
We conducted an intention-to-treat analysis of 68 patients diagnosed with MRSA pneumonia, according to serum vancomycin trough concentrations ( Table 3) . For this analysis, patients with trough concentrations ≥20 mg/l comprised the 'high' group (20.6%; mean concentration 31.7 mg/l), 15 to 20 mg/l comprised the 'optimal' group (23.5%; mean concentration 16.2 mg/l), and <15 mg/l formed the 'low' group (55.9%; mean concentration 7.8 mg/l). Thirty-eight patients (55.9%) had a serum vancomycin concentration below 15 mg/l. There were no differences between the high, optimal and low groups in age, gender or severity of illness. Serum vancomycin concentration was not affected by concomitant treatment with rifampin between each group (high group: 7.1%, optimal group: 37.5%, low group 13.2%).
The treatment failure rate for MRSA pneumonia was 58.8%. The optimal group showed the lowest treatment failure rate (50%) compared with 64.3% failure in the high group and 60.5% failure in the low group, but there were no significant differences between the groups (P=0.801, Figure 2 ). Importantly, lower vancomycin trough levels were associated with a significantly longer duration of vancomycin treatment (high group, 12.5 days; optimal group, 13.1 days; low group, 15.5 days; P=0.008). Among the 40 patients with treatment failure, 18 were switched from vancomycin to linezolid, five were switched from vancomycin to teicoplanin and 17 died. There were no significant differences between the high, optimal and low groups in the use of mechanical ventilation, figure 1: Comparison of the initial and corrected doses of vancomycin after therapeutic drug monitoring, relative to renal function. Significant differences in vancomycin doses were observed in patients with CrCl ≥60 ml/min (*P <0.01) and in those on intermittent haemodialysis (*P=0.01). The corrected dose of vancomycin was higher after therapeutic drug monitoring, compared with the initial dose of vancomycin. CrCl=estimated creatinine clearance, IHD=intermittent haemodialysis, CRRT=continuous renal replacement therapy.
figure 2: Treatment failure (left) and intensive care unit (ICU) mortality (right) for methicillin-resistant Staphylococcus aureus pneumonia, relative to vancomycin trough concentrations. There were no significant differences between the groups (P >0.05).
length of ICU stay, and mortality (P=0.298, 0.749 and 0.947, respectively). The overall pneumonia-related death rate was 48.4%.
DISCUSSION
This study was designed to determine the optimal dose of vancomycin in critically ill patients with pneumonia. More than 50% of the patients failed to attain serum trough concentrations greater than 15 mg/l, and 22.7% of the patients had serum trough concentrations exceeding 20 mg/l. The patients in this study had an average weight of 58 kg and received an initial dose of vancomycin of 37 mg/ kg/day. Considering the average body weight and initial dose, the initial dose of vancomycin was administered appropriately according to the guidelines (15 mg/kg/dose every 12 hours), however in many cases, the serum trough concentration was low 15 . The relatively high proportion of patients in our study with low vancomycin trough concentrations suggests that current vancomycin treatment guidelines may not be optimal in this patient population.
Various factors could affect the pharmacokinetics of antimicrobial agents in critically ill patients, and depending solely on CrCl for determining the vancomycin dosage may not be as precise as it is in healthy individuals. In critically ill patients, factors such as stress-induced changes in renal and metabolic functions, aggressive fluid resuscitation and combined organ failure could influence pharmacokinetics 24 and different methods of haemodialysis could influence the plasma removal rate of the drug 25 . These factors could confound the pharmacokinetic estimations. The suboptimal vancomycin concentrations that were achieved using current dosing regimens may have detrimental effects in critically ill patients with life-threatening infections. Therefore, individual therapeutic drug monitoring (TDM) should be performed in critically ill patients when estimating the optimal drug dosage. The value of this pharmacokinetic method for more rapidly and effectively achieving the therapeutic target range needs to be evaluated in a randomised trial. Another challenge is achieving optimal vancomycin levels in the lung, as its distribution into pulmonary tissue is very low. The serum-to-lung penetration ratio, as measured in the epithelial lining fluid, was 6:1 in critically ill patients receiving vancomycin therapy to treat MRSA pneumonia 9 . Therefore, it is important to maintain a sufficiently high serum trough to ensure the distribution of vancomycin into the lung. Cruciani et al 13 reported that a one gram dose of vancomycin did not achieve a sustained lung concentration above the minimal inhibitory concentration over 12 hours. Several recent studies have compared the continuous and intermittent infusion of vancomycin in ICU patients and found the efficacy of, and tolerance to, the two routes of administration to be comparable 12, 26 . Inappropriately low antibiotic dosing may contribute to the increasing rate of antibiotic resistance 27 and a higher dosing of vancomycin may reduce the development of resistance to this antibiotic. In this study, the low vancomycin trough group underwent a significantly longer duration of vancomycin treatment. We did not test the relationship between vancomycin dose and the development of resistance in this study: however, we note that despite high rates of vancomycin use in treating MRSA isolates in our ICU, the prevalence of MRSA pneumonia did not decrease, suggesting some degree of resistance to vancomycin. For these reasons, we are considering whether strategies such as continuous infusion or high initial loading dose may be more efficacious in our ICU (based on the present study, 46 mg/kg/day may be appropriate). However, we are approaching this with caution because of the high risk of toxicity in critically ill patients receiving higher doses of vancomycin. Many Korean clinicians prescribe vancomycin empirically, starting at 1.0 g q 12 hours (in patients with normal renal function), with further adjustments to the dose after TDM; done infrequently, even though the patients are critically ill. This approach is problematic, leading to low serum vancomycin concentrations and a long duration of use. Therefore, initial administration of a higher dose of vancomycin and subsequent dose adjustment by routine TDM on a daily basis, or a different modality of administration, may be required in critically ill patients.
However, the relationship between higher serum trough concentrations of vancomycin and treatment success rate for MRSA pneumonia remains controversial. We did not identify a relationship between trough concentration of vancomycin and treatment outcome. Our results showed a mean treatment failure rate of 58.8% for MRSA pneumonia and although the highest treatment success rate was obtained with serum trough concentrations of 15 to 20 mg/l, this was not statistically significant (P=0.753). In addition, the mortality rate for MRSA pneumonia was not different in the high, optimal and low groups. Similarly, Jeffres et al 17 reported that higher vancomycin trough concentrations and area under curve values did not correlate with hospital outcomes. In our study, the treatment outcome and ICU mortality were higher than in our two previous studies conducted in the same ICU 28, 29 . This probably reflects the patient populations assessed in the different studies. The present study included all patients with pneumonia, including those with a high use of mechanical ventilation, so they are more likely to have ventilator-associated pneumonia.
Vancomycin-induced nephrotoxicity limits the use of high-dose vancomycin therapy. Although a vancomycin trough concentration of 15 to 20 mg/l is recommended by the American Thoracic Society and Infectious Diseases Society of America guidelines, no large randomised clinical trial to assess the efficacy of this target concentration has been performed. In some studies, high vancomycin trough concentrations of >20 mg/l and a long duration of therapy were associated with an increased rate of acute kidney injury 17, [30] [31] [32] . However, most studies have been limited by their retrospective design and incomplete description of renal toxicity. Therefore, clinicians must carefully consider the available treatment options by assessing the potential benefit for each patient weighed against the risk of vancomycin-associated nephrotoxicity.
This study has several limitations. First, the study was conducted in a single centre. The selection of patients could have been biased and as with all observational, single-centre studies, our findings need to be interpreted cautiously and verified in a multicentre trial. Second, MRSA was not identified in all patients and even in the cases where MRSA was isolated, bronchoalveolar lavage was performed only in a minority of cases. Third, the MIC of MRSA was not measured, limiting further analysis of the treatment outcome in subgroups. Moise-Broder et al 16 have suggested that the area under the 24 hour curve/MIC values of vancomycin predict time-related clinical and bacteriological outcomes in patients with MRSA-related lower respiratory tract infections. In addition, Hidayat et al 18 reported fewer end-of-treatment responses (62 vs 85%) and a higher infection-related mortality rate (24 vs 10%) in patients with a high MIC than in those with a low MIC. Although we did not measure the vancomycin MIC of MRSA isolates, other studies conducted in our ICU showed that MRSA isolates frequently had high vancomycin MICs, leading to slower clinical responses and higher MRSA infection relapse rates 29 . Finally, only one point of TDM after reacting steady state of vancomycin was analysed. We did not measure the resultant trough concentration after TDM. This limitation would have influenced the treatment outcome in these subjects. Further clinical trials are needed to determine whether high dose vancomycin treatment, and dosage adjustments with frequent TDM, do achieve superior clinical outcomes in critically ill patients with MRSA pneumonia with high MIC strains.
CONCLUSION
More than 70% of patients failed to reach optimal therapeutic serum trough concentrations when vancomycin was administered according to current dosage guidelines. A higher dose of vancomycin is necessary to maintain a serum trough concentration of between 15 to 20 mg/l, particularly in critically ill patients with CrCl above 60 ml/minute or those on IHD. However, we did not observe a significant association between vancomycin serum trough concentrations and treatment outcomes.
